Pharmaceuticals Global

Global Oral GLP-1 Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Global Oral GLP-1 Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Global · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.22 Bn Placeholder estimate
Estimate 2025 $5.58 Bn Placeholder estimate
Projected 2034 $67.84 Bn 1,116.6% Adds $62.26 Bn over 9 forecast years
CAGR 2025–2034 32.0% Faster than 98% of 179 Pharmaceuticals markets here
Key players 5
  • Worldwide, the largest is US at $2.25 Bn.
  • Fastest growing: India at 35.4% a year.

Market size projection

Global

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$62.26 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Oral GLP-1 Drugs Market market size by year, Global
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.22 Bn — —
2025 (base) $5.58 Bn +$1.35 Bn —
2026 (forecast) $7.36 Bn +$1.78 Bn +32%
2027 (forecast) $9.72 Bn +$2.36 Bn +74.2%
2028 (forecast) $12.82 Bn +$3.11 Bn +130%
2029 (forecast) $16.93 Bn +$4.10 Bn +203.6%
2030 (forecast) $22.34 Bn +$5.42 Bn +300.7%
2031 (forecast) $29.49 Bn +$7.15 Bn +429%
2032 (forecast) $38.93 Bn +$9.44 Bn +598.3%
2033 (forecast) $51.39 Bn +$12.46 Bn +821.7%
2034 (forecast) $67.84 Bn +$16.45 Bn +1,116.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Global Oral GLP-1 Drugs Market Analysis at a glance
Market size, 2025$5.58 Bn placeholder estimate
Forecast, 2034$67.84 Bn placeholder estimate
Growth (CAGR), 2025–203432.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, application and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics, Viking Therapeutics (see all)
Regulator worldwideWHO prequalificationSource: WHO Prequalification. Checked 14 Nov 2026.
Active clinical trials3 worldwideSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Global Oral GLP-1 Drugs Market Analysis Executive Summary

Oral GLP-1 drugs deliver GLP-1 based therapy as a tablet instead of an injection, making treatment easier for people with diabetes or obesity.

Key segments of the oral GLP-1 Drugs market include drug (Oral Semaglutide, Orforglipron and Danuglipron) and application (Type 2 Diabetes and Obesity).

Bar chart: Global Oral GLP-1 Drugs market size, 2024–2034, placeholder estimates. $4.22 Bn in 2024, $5.58 Bn in 2025 and $67.84 Bn in 2034, 32.0% CAGR.
Global Oral GLP-1 Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Global Oral GLP-1 Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the oral GLP-1 Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the oral GLP-1 Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Oral GLP-1 Drugs Market in Global

The oral GLP-1 Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Oral GLP-1 Drugs Market in Global

Oral GLP-1 Drugs worldwide: rules, payment and research

There is no single global regulator; WHO prequalification of medicines, vaccines and diagnostics guides buying by UN agencies and many countries.⁠[1] WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.⁠[2] ClinicalTrials.gov lists 3 studies on Oral GLP-1 Drugs that are recruiting, active or about to start worldwide.⁠[3]

[1] WHO Prequalification. Checked 14 Nov 2026.

[2] World Health Organization, universal health coverage. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oral GLP-1 Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Global.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Oral GLP-1 Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Oral GLP-1 Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Oral GLP-1 Drugs market worldwide?
Placeholder estimate: about $5.58 Bn in 2025, rising to about $67.84 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Oral GLP-1 Drugs market worldwide growing?
Placeholder estimate: about 32.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Oral GLP-1 Drugs market report cover?
The report splits the market by drug (Oral Semaglutide, Orforglipron, Danuglipron, Others), application (Type 2 Diabetes, Obesity) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Oral GLP-1 Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics and Viking Therapeutics.
What is driving the Oral GLP-1 Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market.
Who regulates Oral GLP-1 Drugs worldwide?
There is no single global regulator; WHO prequalification of medicines, vaccines and diagnostics guides buying by UN agencies and many countries. Source: WHO Prequalification. Checked 14 Nov 2026.
How is healthcare paid for worldwide?
WHO reports that 4.5 billion people were not fully covered by essential health services in 2021. Source: World Health Organization, universal health coverage. Checked 14 Nov 2026.
How many clinical trials on Oral GLP-1 Drugs are running worldwide?
3 studies are recruiting, active or about to start worldwide, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
How much research is published on Oral GLP-1 Drugs?
PubMed lists 65 papers on Oral GLP-1 Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Global

See all

Related on obesity and diabetes

See the topic